Sensei Biotherapeutics (SNSE) Appoints William Ringo as Board Chair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
March 9, 2022 4:05 PM ESTBOSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of William (Bill) Ringo, MBA, as chair of its Board of Directors.
Bill is an accomplished life sciences leader who has been instrumental to the success of multiple pharmaceutical companies and biotechs. His experience and insights will be invaluable to us as we advance our business objectives and pipeline of potentially transformative oncology therapeutics, said John Celebi, president and chief executive... More
